Skip to main content
Top

Open Access 09-05-2024 | Atopic Dermatitis | Systematic Review

Treatment Preference Research in Atopic Dermatitis: A Systematic Review of Quantitative Studies

Authors: Katja C. Heinz, Charlotte Beaudart, Damon Willems, Mickaël Hiligsmann

Published in: The Patient - Patient-Centered Outcomes Research

Login to get access

Abstract

Background

Treatment preference research can support shared and informed decision making for currently available atopic dermatitis (AD) treatments, and simultaneously guide research and development for future therapies. In this systematic literature review, we aimed to provide an overview of preferences for AD treatments.

Methods

This systematic literature review was conducted in the Medline and Embase (via Ovid) databases, supplemented by manual searching. Quantitative research published from 2010 to September 2023 that investigated preferences for AD treatments were included. Quality assessment was conducted by using the purpose, respondents, explanation, findings, significance checklist, and a checklist developed by the Professional Society for Health Economics and Outcomes Research.

Results

In total, 207 references were screened after removing duplicates and 15 studies were included. Most studies were conducted in the US, followed by European countries. On average, people directly or indirectly affected by AD rate efficacy and treatment-related risk as the most important criteria when choosing an AD therapy. Participants are willing to increase risks in order to have a higher chance of achieving a certain benefit, e.g. reduction in itch or clearer skin. Participants have preferences for different modes of administration. On average, 68% (all full-text studies) and 87% (only discrete choice experiments [DCEs]) of quality criteria per reference were rated as fulfilled. DCEs received generally higher quality assessment scores than non-DCEs.

Conclusions

This review revealed that AD treatment preference research is limited. Diverse study designs hampered comparison and synthesis of the results. We recommend conducting more DCEs in this field to increase the likelihood of AD patients receiving the therapy that best fits their individual needs and preferences.

Clinical Trials Registration

This protocol was published in PROSPERO (ID: CRD42023468757).
Appendix
Available only for authorised users
Literature
1.
go back to reference Williams HC. Atopic dermatitis: the epidemiology, causes and prevention of atopic eczema. Cambridge: Cambridge University Press; 2000.CrossRef Williams HC. Atopic dermatitis: the epidemiology, causes and prevention of atopic eczema. Cambridge: Cambridge University Press; 2000.CrossRef
2.
go back to reference Love I, White K. Atopic dermatitis/atopic eczema: disease landscape & forecast. Decision Resources Group; 2020. Love I, White K. Atopic dermatitis/atopic eczema: disease landscape & forecast. Decision Resources Group; 2020.
15.
go back to reference Centre for Reviews and Dissemination. Systematic Reviews: CRD’s guidance for undertaking reviews in health care. York: University of York; 2009. Centre for Reviews and Dissemination. Systematic Reviews: CRD’s guidance for undertaking reviews in health care. York: University of York; 2009.
17.
go back to reference Nelson HD. Systematic reviews to answer health care questions. Philadelphia: Wolters Kluwer Health; 2014. Nelson HD. Systematic reviews to answer health care questions. Philadelphia: Wolters Kluwer Health; 2014.
19.
go back to reference Sharma P, Kularatna S, Abell B, Eagleson K, Vo LK, Halahakone U, et al. Preferences in the design and delivery of neurodevelopmental follow-up care for children: a systematic review of discrete choice experiments. Patient Prefer Adher. 2023;17:2325–41. https://doi.org/10.2147/PPA.S425578.CrossRef Sharma P, Kularatna S, Abell B, Eagleson K, Vo LK, Halahakone U, et al. Preferences in the design and delivery of neurodevelopmental follow-up care for children: a systematic review of discrete choice experiments. Patient Prefer Adher. 2023;17:2325–41. https://​doi.​org/​10.​2147/​PPA.​S425578.CrossRef
29.
go back to reference Cadmus SD, Sebastian KR, Warren D, Hovinga CA, Croce EA, Reveles LA, et al. Efficacy and patient opinion of wet-wrap dressings using 0.1% triamcinolone acetonide ointment vs cream in the treatment of pediatric atopic dermatitis: a randomized split-body control study. Pediatr Dermatol. 2019;36:437–41. https://doi.org/10.1111/pde.13830. Cadmus SD, Sebastian KR, Warren D, Hovinga CA, Croce EA, Reveles LA, et al. Efficacy and patient opinion of wet-wrap dressings using 0.1% triamcinolone acetonide ointment vs cream in the treatment of pediatric atopic dermatitis: a randomized split-body control study. Pediatr Dermatol. 2019;36:437–41. https://​doi.​org/​10.​1111/​pde.​13830.
36.
go back to reference Prajapati VH, Eichenfield LF, Schuttlelaar ML, Ladizinski B, Vigna N, Chen N, et al. Preference for oral versus injectable treatment in adults with moderate-to-severe atopic dermatitis: results from the phase 3b heads up clinical trial. In: 4th annual revolutionizing atopic dermatitis (RAD) conference 9–11 April 2022; Baltimore, MD. Prajapati VH, Eichenfield LF, Schuttlelaar ML, Ladizinski B, Vigna N, Chen N, et al. Preference for oral versus injectable treatment in adults with moderate-to-severe atopic dermatitis: results from the phase 3b heads up clinical trial. In: 4th annual revolutionizing atopic dermatitis (RAD) conference 9–11 April 2022; Baltimore, MD.
Metadata
Title
Treatment Preference Research in Atopic Dermatitis: A Systematic Review of Quantitative Studies
Authors
Katja C. Heinz
Charlotte Beaudart
Damon Willems
Mickaël Hiligsmann
Publication date
09-05-2024
Publisher
Springer International Publishing
Published in
The Patient - Patient-Centered Outcomes Research
Print ISSN: 1178-1653
Electronic ISSN: 1178-1661
DOI
https://doi.org/10.1007/s40271-024-00698-3
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare
Live Webinar | 01-10-2024 | 12:30 (CEST)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Live: Tuesday 1st October 2024, 12:30-14:00 (CEST)

In this live webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts will discuss the very latest data on the safety, efficacy and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL, as presented at ASH 2023, EU CAR-T 2024, and EHA 2024. 

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by: Novartis Pharma AG

Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare